Pre-Close Trading Update

RNS Number : 8336J

Alliance Pharma PLC

06 July 2011

 



For immediate release

6 July 2011

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Pre-Close Trading Update

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces a pre-close trading update ahead of the announcement of its interim results for the six months ended 30 June 2011.

Recent trading has been in line with management's expectations.  Sales for the six months ended 30 June 2011 were approximately £24.4m, £1.0m ahead of the first half of 2010.  As previously reported, sales of Deltacortril^TM / enteric coated prednisolone have been impacted by greater competition, but the promoted portfolios of Dermatology and Oncology continue to grow well, in particular Hydromol^TM, which has grown 26% compared with the first half of 2010.

Following the acquisition of Anbesol^TM and Ashton & Parsons^TM in April 2011 we are pleased with the demand shown for these products in the first two months of ownership.

The Company's interim results are due to be announced on 7 September 2011.

For further information:

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk
Buchanan Communications	+ 44 (0) 20 7466 5000
Mark Court / Jessica Fontaine
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Oliver Cardigan
Corporate Broking: David Poutney

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and, following the Cambridge Laboratories acquisition, owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections.  Alliance's sales are mainly prescription driven.  Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 

END

 

 

TSTSSLFMIFFSELW